Executives On The Move: Changes to Development Posts At Amgen, Orchard Therapeutics, Tilray, Genentech And NGM Biopharma
Executive Summary
It’s all about development — Amgen Development VP now CTO at rare disease firm Orchard Therapeutics, and Goldman Sachs exec is chief corporate development officer at pharma/cannabis business Tilray. Meanwhile, Genentech early clinical development VP switches to CMO spot at cardio-metabolic and liver disease company NGM Biopharma.